AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO ASCERTAIN THE OPTIMAL STARTING DOSE OF MIRCERA GIVEN SUBCUTANEOUSLY FOR THE MAINTENANCE TREATMENT OF ANEMIA IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS OR NOT YET ON DIALYSIS.
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Methoxy polyethylene glycol-epoetin beta (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Roche
- 04 Jul 2018 Planned End Date changed from 29 Oct 2021 to 30 Oct 2021.
- 04 Jul 2018 Planned primary completion date changed from 29 Oct 2021 to 30 Oct 2021.
- 25 Jun 2018 Planned End Date changed from 28 Oct 2021 to 29 Oct 2021.